Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report report published on Wednesday morning, Benzinga reports. The brokerage currently has a $14.00 target price on the stock.

Separately, HC Wainwright started coverage on Coya Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating and a $18.00 target price for the company.

Coya Therapeutics Stock Down 2.6 %

Shares of NASDAQ COYA opened at $7.04 on Wednesday. The stock has a market cap of $107.15 million, a PE ratio of -9.64 and a beta of 0.58. Coya Therapeutics has a 52-week low of $4.40 and a 52-week high of $10.69. The business has a 50-day moving average price of $6.91 and a 200 day moving average price of $7.08.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company had revenue of $3.43 million during the quarter. Sell-side analysts anticipate that Coya Therapeutics will post -1.27 earnings per share for the current year.

Institutional Trading of Coya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GHP Investment Advisors Inc. purchased a new stake in Coya Therapeutics during the 3rd quarter valued at approximately $169,000. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics during the 2nd quarter worth approximately $101,000. Gilbert & Cook Inc. purchased a new position in shares of Coya Therapeutics during the 2nd quarter worth approximately $61,000. Finally, Vanguard Group Inc. raised its stake in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.